Kymera Therapeutics, Inc.

Advancing oral small-molecule degraders in immunology, led by a first-in-class STAT6 degrader.

Back to company catalog

Immunology & inflammation · Targeted protein degradation · Clinical (Phase 2b)

Compare report options